Search results
Results from the WOW.Com Content Network
Management of the dawn phenomenon varies by patient and thus should be done with regular assistance from a patient's physician. Some treatment options include, but are not limited to, dietary modifications, increased exercise before breakfast and during the evening, and oral anti-hyperglycemic medications if a patient's HbA1c is > 7%.
Chronic Somogyi rebound is a contested explanation of phenomena of elevated blood sugars experienced by diabetics in the morning. Also called the Somogyi effect and posthypoglycemic hyperglycemia, it is a rebounding high blood sugar that is a response to low blood sugar. [1]
It can be confused with the Dawn phenomenon and whether or not Somogyi's theory is actually correct is still contested. [10] In 1949, Somogyi argued against the use of high doses of insulin on the grounds that it was a potentially dangerous form of treatment.
Dawn phenomenon A sudden rise in blood glucose levels in the early morning hours. This condition sometimes occurs in people with type 1 (formerly known as insulin-dependent) diabetes and (rarely) in people with type 2 (formerly known as noninsulin-dependent) diabetes. Unlike the Somogyi effect, it is not a result of an insulin reaction.
Chronic Somogyi rebound; D. Dawn phenomenon; Diabesity; Diabetes and deafness; Diabetes in Australia; Diabetes in cats; Diabetes in dogs; Diabetes in India;
Peter Somogyi is the former Director of the Medical Research Council Anatomical Neuropharmacology Unit at the University Department of Pharmacology, University of Oxford, England. [ 1 ] Somogyi’s discoveries relate to understanding ways in which networks of neurons work in the brain.
Somogyi was born in 1933, in Budapest, Kingdom of Hungary, into a rich Jewish family. She attended a private elementary school until World War II, when she hid in a Catholic convent to avoid capture by the Nazis. [1] Her family was reunited at the end of the war, but her father was arrested soon after. She married at age 17.
Following the discovery of the isoelectric point for insulin, Eli Lilly hoped to win an insulin production patent for itself but could not due to a similar and concurrent discovery by Michael Somogyi, Phillip Shaffer and E. A. Doisy at Washington University in St. Louis, news of which had already reached the researchers in Toronto.